Director Christophe Jean filed a Form 4 with the SEC on November 18, 2026, disclosing the exercise of stock options and the sale of common stock in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on November 17, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Option exercise: Jean exercised 10,000 stock options at an exercise price of $34.89 per share on November 17, 2026.
- Share sales at three prices: Jean sold 5,000 shares at $106.81, 2,500 shares at $110.00, and 2,500 shares at $115.00, all on November 17, 2026.
- Post-transaction ownership: Following the reported transactions, Jean directly held 11,712 shares of common stock.
- Options extinguished: The 10,000 stock options exercised now show 0 derivative securities beneficially owned following the transactions.
- 10b5-1 plan: According to the filing, all exercise and sale transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2026.
- Option expiration: The exercised options carried an expiration date of June 5, 2028, and had fully vested upon the earlier of one year from grant or the date of the issuer's next annual stockholder meeting.
Jean's Option Exercise and Stock Sales at Rhythm Pharmaceuticals
Director Christophe Jean reported four transactions in Rhythm Pharmaceuticals common stock, all occurring on November 17, 2026, according to the Form 4 filed on November 18, 2026. Jean first exercised 10,000 stock options at an exercise price of $34.89 per share, with the options carrying an expiration date of June 5, 2028. The filing states that those options had fully vested upon the earlier of one year from the date of grant or the date of the issuer's next annual meeting of stockholders.
Following the option exercise, Jean disposed of all 10,000 shares acquired through three separate sale transactions. The filing records a sale of 5,000 shares at $106.81 per share, a sale of 2,500 shares at $110.00 per share, and a sale of 2,500 shares at $115.00 per share, all on the same date. Prior to the option exercise, Jean's directly held position stood at 11,712 shares after the first transaction in the sequence; after all four transactions were completed, the filing shows 11,712 shares of common stock directly held.
The filing notes that "the exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026." The Form 4 was signed by Stephen Vander Stoep as attorney-in-fact for Christophe Jean and submitted on November 18, 2026. Jean is identified in the filing solely as a director of Rhythm Pharmaceuticals, Inc.
What Was Disclosed
Rhythm Pharmaceuticals director Christophe Jean disclosed the exercise of 10,000 stock options at $34.89 and the sale of 10,000 shares across three price points on November 17, 2026, all under a pre-established Rule 10b5-1 plan, leaving a direct holding of 11,712 shares.




Please wait processing your request...